Drugs / Lopinavir/Ritonavir
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04372628 Comparator | Jun 2020 → Dec 2021 | COVID-19 | Vanderbilt University Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lopinavir/Ritonavir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04372628 ↗ |
| Known as | LPV/r | “lopinavir/ritonavir (LPV/r) for early treatment” PMID 36581186 ↗ Dec 2022 |
| Route | Oral | “Lopinavir/Ritonavir 400 mg/100 mg orally twice daily for twenty-eight doses (Days 1-14)” NCT04372628 ↗ |